Drug reference
sotorasib
covalent inhibitor
covalent inhibitor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
D
FDA category + note
Mechanism
Sotorasib gains potency and specificity by forming a covalent bond with a cysteine side chain present in an oncogenic mutant form of KRAS (KRAS G12C) but not in normal KRAS.
Indications
cancer (specifically targeting KRAS G12C mutation)locally advanced or metastatic NSCLC who have received at least one prior systemic therapy (KRAS G12C-mutant oncogenic)
Pharmacokinetics
Half-life
5 h (mean elimination)
Metabolism
nonenzymatic conjugation and CYP3A
Side effects
Common
diarrheanausealow-grade hepatotoxicity
Serious
- pneumonitis
- dyspnea
Pregnancy & lactation
Pregnancy
D
Related guidelines
Ask House about sotorasib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team